Compare · BRNS vs NVO
BRNS vs NVO
Side-by-side comparison of Barinthus Biotherapeutics plc (BRNS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRNS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 5744.3x BRNS ($30.2M).
- Over the past year, BRNS is down 44.9% and NVO is down 30.4% - NVO leads by 14.6 points.
- NVO has hit the wire 3 times in the past 4 weeks while BRNS has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for BRNS).
- Company
- Barinthus Biotherapeutics plc
- Novo Nordisk A/S
- Price
- $0.76+6.03%
- $38.82-1.05%
- Market cap
- $30.2M
- $173.66B
- 1M return
- +27.17%
- -10.14%
- 1Y return
- -44.92%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BRNS
- SEC Form 15-12G filed by Barinthus Biotherapeutics plc
- SEC Form EFFECT filed by Barinthus Biotherapeutics plc
- Amendment: Former 10% owner Oxford Science Enterprises Plc closing all direct ownership in the company (SEC Form 4)
- SEC Form 25 filed by Barinthus Biotherapeutics plc
- Director Scheeren Joseph returned 23,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Phillips Anne M. returned 3,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wright Robin returned 48,256 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Morgon Pierre A. returned 10,506 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Hammacher Alex returned 3,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Hooftman Leon was granted 361,530 units of Ordinary Shares and returned 361,530 units of Ordinary Shares to the company (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank